MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 584260 | Name: Paroxetine
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Paroxetine is a potent and one of the most specific selective serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibitors (SSRIs).It acts by binding to ST (serotonin transporter/SERT) with high affinity. Paroxetine binds to the pre-synaptic serotonin transporter complex resulting in negative allosteric modulation of the complex thereby blocking reuptake of serotonin by the pre-synaptic transporter. Paroxetine HCl has also displayed a high affinity for muscarinic acetylcholine receptors.

Chemical Structure

Paroxetine
Paroxetine
CAS#61869-08-7 (free base)

Theoretical Analysis

MedKoo Cat#: 584260

Name: Paroxetine

CAS#: 61869-08-7 (free base)

Chemical Formula: C19H20FNO3

Exact Mass: 329.1427

Molecular Weight: 329.37

Elemental Analysis: C, 69.29; H, 6.12; F, 5.77; N, 4.25; O, 14.57

Price and Availability

Size Price Availability Quantity
250mg USD 350.00 2 Weeks
500mg USD 550.00 2 Weeks
1g USD 850.00 2 Weeks
2g USD 1,250.00 2 Weeks
5g USD 2,650.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
61869-08-7 (free base) 64006-44-6 (maleate) 78246-49-8 (HCl) 72471-80-8 (acetate) 217797-14-3 (mesylate) 110429-35-1 (HCl hydrate)
Synonym
Paroxetine
IUPAC/Chemical Name
Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, (3S,4R)-
InChi Key
AHOUBRCZNHFOSL-YOEHRIQHSA-N
InChi Code
InChI=1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1
SMILES Code
FC1=CC=C([C@H]2[C@H](COC3=CC=C(OCO4)C4=C3)CNCC2)C=C1
Appearance
Solid powder
Purity
>97% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 329.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Wang Y, Zhang A, Dilinuer A, Hao L, Hu Z, Jia W. Meta-analysis of acupuncture combined with paroxetine in the treatment of depression. Am J Transl Res. 2022 Dec 15;14(12):8429-8436. PMID: 36628233; PMCID: PMC9827301. 2: Zeng M, Gong A, Wu Z. Paroxetine combined with traditional chinese medicine prescriptions in the treatment of postpartum depression: A systematic review of randomized controlled trials. Front Neuroendocrinol. 2022 Oct;67:101019. doi: 10.1016/j.yfrne.2022.101019. Epub 2022 Aug 1. PMID: 35926637. 3: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Paroxetine. 2022 May 15. PMID: 30000249. 4: David PS, Smith TL, Nordhues HC, Kling JM. A Clinical Review on Paroxetine and Emerging Therapies for the Treatment of Vasomotor Symptoms. Int J Womens Health. 2022 Mar 10;14:353-361. doi: 10.2147/IJWH.S282396. PMID: 35300283; PMCID: PMC8921794. 5: Mother To Baby | Fact Sheets [Internet]. Brentwood (TN): Organization of Teratology Information Specialists (OTIS); 1994–. Paroxetine. 2021 Mar 1. PMID: 35952169. 6: Kowalska M, Nowaczyk J, Fijałkowski Ł, Nowaczyk A. Paroxetine-Overview of the Molecular Mechanisms of Action. Int J Mol Sci. 2021 Feb 7;22(4):1662. doi: 10.3390/ijms22041662. PMID: 33562229; PMCID: PMC7914979. 7: Santos J, Proença MF, Rodrigues AJ, Patrício P, Domingues HS. Recent Advances in the Synthesis of the Antidepressant Paroxetine. Curr Med Chem. 2021;28(15):2960-2973. doi: 10.2174/0929867327666201026144848. PMID: 33106133. 8: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Paroxetine. 2020 Apr 8. PMID: 31643629. 9: Li L, Han Z, Li L, Han L, Yan B. Effectiveness of Paroxetine for Poststroke Depression: A Meta-Analysis. J Stroke Cerebrovasc Dis. 2020 May;29(5):104664. doi: 10.1016/j.jstrokecerebrovasdis.2020.104664. Epub 2020 Feb 21. PMID: 32093988. 10: Feduccia AA, Jerome L, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R. Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline. Front Psychiatry. 2019 Sep 12;10:650. doi: 10.3389/fpsyt.2019.00650. PMID: 31572236; PMCID: PMC6751381. 11: Nevels RM, Gontkovsky ST, Williams BE. Paroxetine-The Antidepressant from Hell? Probably Not, But Caution Required. Psychopharmacol Bull. 2016 Mar 1;46(1):77-104. PMID: 27738376; PMCID: PMC5044489. 12: Wei D, Chen Y, Wu C, Wu Q, Yao L, Wang Q, Wang XQ, Yang KH. Effect and safety of paroxetine for vasomotor symptoms: systematic review and meta- analysis. BJOG. 2016 Oct;123(11):1735-43. doi: 10.1111/1471-0528.13951. Epub 2016 Apr 7. PMID: 27062457. 13: Bérard A, Iessa N, Chaabane S, Muanda FT, Boukhris T, Zhao JP. The risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016 Apr;81(4):589-604. doi: 10.1111/bcp.12849. Epub 2016 Jan 26. PMID: 26613360; PMCID: PMC4799922. 14: Bhat IA, Shannon KD, Ara A, Coe I. Ninety-six hours ordeal of priapism induced by paroxetine--A case report and literature review. Int J Psychiatry Med. 2015;50(3):326-34. doi: 10.1177/0091217415610312. Epub 2015 Oct 5. PMID: 26443710. 15: Carroll DG, Lisenby KM, Carter TL. Critical appraisal of paroxetine for the treatment of vasomotor symptoms. Int J Womens Health. 2015 Jun 18;7:615-24. doi: 10.2147/IJWH.S50804. PMID: 26124682; PMCID: PMC4476484. 16: Slaton RM, Champion MN, Palmore KB. A review of paroxetine for the treatment of vasomotor symptoms. J Pharm Pract. 2015 Jun;28(3):266-74. doi: 10.1177/0897190014544785. Epub 2014 Aug 8. PMID: 25107421. 17: Carris N, Kutner S, Reilly-Rogers S. New pharmacological therapies for vasomotor symptom management: focus on bazedoxifene/conjugated estrogens and paroxetine mesylate. Ann Pharmacother. 2014 Oct;48(10):1343-9. doi: 10.1177/1060028014543099. Epub 2014 Jul 15. PMID: 25028744. 18: Purgato M, Papola D, Gastaldon C, Trespidi C, Magni LR, Rizzo C, Furukawa TA, Watanabe N, Cipriani A, Barbui C. Paroxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev. 2014 Apr 3;2014(4):CD006531. doi: 10.1002/14651858.CD006531.pub2. PMID: 24696195; PMCID: PMC10091826. 19: Weber L, Thacker HL. Paroxetine: a first for selective serotonin reuptake inhibitors - a new use: approved for vasomotor symptoms in postmenopausal women. Womens Health (Lond). 2014 Mar;10(2):147-54. doi: 10.2217/whe.14.3. PMID: 24601805. 20: Sanchez C, Reines EH, Montgomery SA. A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike? Int Clin Psychopharmacol. 2014 Jul;29(4):185-96. doi: 10.1097/YIC.0000000000000023. PMID: 24424469; PMCID: PMC4047306.